v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 28, 2026
Jun. 29, 2025
Cash Flows from Operating Activities:    
Net income $ 172,649 $ 547,688
Adjustments to reconcile net income to net cash used by operating activities:    
Asset impairments 3,626 6,329
Depreciation and amortization 256,125 250,967
Share-based compensation expense 11,905 9,973
Equity in earnings of affiliates, net of tax (2,953) (4,191)
Cash dividends from affiliated companies 4,360 5,731
Net loss on disposition of assets 1,397 635
Net gain on divestiture of business (775) (619,507)
Pension and postretirement plan expense 7,841 8,731
Pension and postretirement plan contributions (10,397) (10,458)
Net increase/(decrease) in deferred taxes 2,516 (55,633)
Change in assets and liabilities, net of effects from acquisitions, divestitures and foreign currency adjustments:    
Trade accounts receivable (180,618) (67,668)
Inventories (152,106) (203,808)
Payable to suppliers 31,607 8,056
Prepaid expenses (33,641) 9,000
Income taxes payable and other income tax items (100,698) 197,664
Accrued expenses and other assets and liabilities (78,146) (98,162)
Net cash used by operating activities (67,308) (14,653)
Cash Flows from Investing Activities:    
Purchases of property, plant and equipment (125,756) (187,483)
Cost of acquisition, net of cash acquired [1] 0 16,528
Proceeds from the sale of business, net [2] (13,076)  
Proceeds from the sale of business, net [2]   1,814,930
Proceeds from the sale of assets, net 1,883 1,090
Investments in affiliated companies and other net investing proceeds 4,452 242
Net cash (used)/provided by investing activities (132,497) 1,645,307
Cash Flows from Financing Activities:    
Proceeds from issuance of debt 38,690 36,969
Principal repayment of debt (38,106) (2,060,445)
Net change in commercial paper 116,000 354,600
Net increase in book cash overdrafts 3,854 6,476
Payment of loan financing costs (506) 0
Dividends paid to noncontrolling interests 0 (243)
Cash dividends (105,790) (103,558)
Payments for share repurchases (7,011) (10,576)
Net cash provided/(used) by financing activities 7,131 (1,776,777)
Effects of Exchange Rate Changes on Cash (17,076) 32,863
Net Decrease in Cash and Cash Equivalents (209,750) (113,260)
Cash and cash equivalents at beginning of period 378,398 443,060
Cash and cash equivalents at end of period $ 168,648 $ 329,800
[1] During 2025, the Company received $16,528 in a final net working capital settlement related to the acquisition of Eviosys (as defined in Note 4).
[2] During 2026, cash proceeds from the sale of businesses of $4,000 were offset by the Company’s payment of final net working capital settlements of $15,211 and $1,865 to the buyers of TFP (as defined in Note 1) and ThermoSafe (as defined in Note 1), respectively.